Jeffrey C. Lightcap - 07 Aug 2025 Form 3 Insider Report for Heartflow, Inc. (HTFL)

Role
Director
Signature
/s/ Angela Ahmad, Attorney-in-Fact for Jeffrey C. Lightcap
Issuer symbol
HTFL
Transactions as of
07 Aug 2025
Net transactions value
$0
Form type
3
Filing time
07 Aug 2025, 21:15:02 UTC
Previous filing
31 Mar 2023
Next filing
17 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lightcap Jeffrey C Director C/O HEARTFLOW, INC., 331 E. EVELYN AVENUE, MOUNTAIN VIEW /s/ Angela Ahmad, Attorney-in-Fact for Jeffrey C. Lightcap 07 Aug 2025 0001519465

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding HTFL Series C Preferred Stock 07 Aug 2025 Common Stock 624,471 By HealthCor Partners Fund II, L.P. F1, F2
holding HTFL Series C Preferred Stock 07 Aug 2025 Common Stock 1,248,939 By HealthCor Partners Fund, L.P. F1, F2
holding HTFL Series D Preferred Stock 07 Aug 2025 Common Stock 1,630,231 By HCPCIV 1, LLC F2, F3
holding HTFL Series D Preferred Stock 07 Aug 2025 Common Stock 208,604 By HealthCor Partners Fund II, L.P. F2, F3
holding HTFL Series E Preferred Stock 07 Aug 2025 Common Stock 1,099,378 By HCPCIV 1, LLC F2, F4
holding HTFL Series F Preferred Stock 07 Aug 2025 Common Stock 1,337,337 By HCPCIV 1, LLC F2, F5
holding HTFL Series F-1 Preferred Stock 07 Aug 2025 Common Stock 452,528 By HCPCIV 1, LLC F2, F5
holding HTFL Convertible Promissory Note 07 Aug 2025 Common Stock $1,460,234 By HCPCIV 1, LLC F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series C preferred stock is convertible on a 1-to-0.5764 basis into shares of Heartflow, Inc.'s ("Heartflow") common stock and has no expiration date. The Series C preferred stock will automatically convert into the underlying shares of common stock upon the closing of Heartflow's initial public offering. The conversion rate gives effect to the 1-for-2.92 reverse stock split of Heartflow common stock, which became effective on July 31, 2025.
F2 Mr. Lightcap is a controlling member of each of HCPCIV 1, LLC, HealthCor Partners Fund II, L.P. and HealthCor Partners Fund, L.P. and may be deemed to have voting and dispositive power with respect to the shares. Mr. Lightcap disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3 Each share of Series D preferred stock is convertible on a 1-to-0.6467 basis into shares of Heartflow's common stock and has no expiration date. The Series D preferred stock will automatically convert into the underlying shares of common stock upon the closing of Heartflow's initial public offering. The conversion rate gives effect to the 1-for-2.92 reverse stock split of Heartflow's common stock, which became effective on July 31, 2025.
F4 Each share of Series E preferred stock is convertible on a 1-to-0.6951 basis into shares of Heartflow's common stock and has no expiration date. The Series E preferred stock will automatically convert into the underlying shares of common stock upon the closing of Heartflow's initial public offering. The conversion rate gives effect to the 1-for-2.92 reverse stock split of Heartflow's common stock, which became effective on July 31, 2025.
F5 Each share of Series F preferred stock and Series F-1 preferred stock is convertible on a 1-to-0.3425 basis into shares of Heartflow's common stock and has no expiration date. The Series F preferred stock and Series F-1 preferred stock will automatically convert into the underlying shares of common stock upon the closing of Heartflow's initial public offering. The conversion rate gives effect to the 1-for-2.92 reverse stock split of Heartflow's common stock, which became effective on July 31, 2025.
F6 Represents the outstanding principal amount of a convertible promissory note held by HCPCIV 1, LLC, which will automatically convert upon consummation of Heartflow's initial public offering into shares of common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. These shares of common stock issuable upon conversion of the convertible promissory note have no expiration date.

Remarks:

Remarks: Exhibit 24 - Power of Attorney.